Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Adocia    ADOC   FR0011184241

ADOCIA (ADOC)
Mes dernières consult.
Most popular
Delayed Quote. Delayed  - 08/16 05:35:00 pm
18.25 EUR   --.--%
07/14ADOCIA SAS : half-yearly earnings release
04/18 ADOCIA : announces first quarter 2017 financial results
04/13ADOCIA SAS : quaterly sales release
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Adocia
Operates as a clinical-stage biotechnology company

Adocia SA operates as a clinical-stage biotechnology company, which engages in the development of medicines from already approved therapeutic agents.

Its product pipeline includes BioChaperone PDGF, which is in Phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone insulin that is in Phase I/II clinical trials, as well as in pre-clinical staged for the treatment of diabetes; and Driveln, which is in preclinical stage for the treatment of oncology.

The company was founded by Gérard Soula, OLivier Soula, and Rémi Soula on December 16, 2005 and is headquartered in Lyon, France.



Number of employees : 125 persons.
Sales per Businesses
20152016Delta
EUR (in Million)%EUR (in Million)%
Regenerating Medicine36.94100%22.49100% -39.12%
Sales per Regions
20152016Delta
EUR (in Million)%EUR (in Million)%
France36.94100%22.49100% -39.12%
Managers
NameAgeSinceTitle
Gérard Soula PhD, MBA692005Chairman, President & Chief Executive Officer
Valérie Danaguezian-2006Chief Financial Officer & Administrative Director
Olivier Soula PhD, MBA482005Director, Deputy General Manager, Director-R&D
Stanislav Glezer MD, MBA-2017Chief Medical Officer
Olivier Martinez PhD, MBA47-Director
Laurent Arthaud55-Director
Dominique Takizawa602011Independent Director
Ekaterina Smirnyagina, PhD502013Independent Director
Rémi Soula PhD, MBA-2005Director-Business Development
David Duracher, PhD--Director-Pharmaceutical Development
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Share A 1 6,861,763 5,262,639 76.7% 6,671 0.1% 76.7%
Shareholders
NameEquities%
Gérard Soula PhD, MBA 898,463 13.1%
BPIFrance Investissement SAS 738,639 10.8%
La Société Hospitalière d'Assurances Mutuelles SA 320,000 4.66%
Rémi Soula PhD, MBA 300,490 4.38%
Olivier Soula PhD, MBA 297,490 4.34%
Norges Bank Investment Management 82,675 1.20%
ACG Management SAS 67,439 0.98%
Aviva Investors France SA 55,277 0.81%
CM-CIC Asset Management SA 50,080 0.73%
CPR Asset Management SA 46,761 0.68%
Sector Bio Therapeutic Drugs
1st jan.Capitalization (M$)
ADOCIA-70.08%147
AMGEN17.41%124 074
CELGENE CORPORATION13.49%102 777
GILEAD SCIENCES2.11%95 489
REGENERON PHARMACEUTICALS29.27%50 637
VERTEX PHARMACEUTICALS107.30%38 504
ACTELION23.24%30 604
GENMAB15.77%13 123
EXELIXIS, INC.80.48%7 909
KITE PHARMA INC182.78%7 251
BIOVERATIV INC0.00%6 189
TESARO INC-15.79%6 177
NEUROCRINE BIOSCIENCES, INC.39.64%4 767
TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.-16.64%4 649
BLUEBIRD BIO INC56.56%4 424
HUALAN BIOLOGICAL ENGINEERING INC--.--%3 990
PEPTIDREAM INC-42.60%3 556
CLOVIS ONCOLOGY INC61.82%3 513
BIOCON LTD10.68%3 262
JUNO THERAPEUTICS INC49.71%3 016
AVEXIS INC95.71%2 982
Connections : Adocia
Company contact information
115 avenue Lacassagne
FR-69003 Lyon
France

Phone : +33 (0)4 72 610 610
Fax : +33 (0)4 72 36 39 67
Internet : http://www.adocia.com
Markets and indexes
- PEA / SRD eligible : YES / YES
- Euronext Paris
- Compartiment B
- CAC All Shares / CAC All-Tradable, CAC Mid Small, CAC PME, CAC Small, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME, Tech 40
Stock Exchange Codes
- ISIN Code :  FR0011184241
- Bloomberg Code :  ADOC:FP
- Reuters Code :  ADOC.PA
- Datastream Code :  
© 2017 People , Fundamentals and Ownership    © 2017 Cofisem